Results 1 to 10 of about 55,383 (254)

Screening of FDA-Approved Drugs Using a MERS-CoV Clinical Isolate from South Korea Identifies Potential Therapeutic Options for COVID-19 [PDF]

Viruses, 2021
Therapeutic options for coronaviruses remain limited. To address this unmet medical need, we screened 5406 compounds, including United States Food and Drug Administration (FDA)-approved drugs and bioactives, for activity against a South Korean Middle ...
Meehyun Ko, So Young Chang, Soo Young Byun, Aleksandr Ianevski, Inhee Choi, Anne-Laure Pham Hung d’Alexandry d’Orengiani, Erlend Ravlo, Wei Wang, Magnar Bjørås, Denis E. Kainov, David Shum, Ji-Young Min, Marc P. Windisch   +12 more
doaj   +4 more sources

Hemodynamic Profile of the Cardiotonic Agent Pimobendan

Journal of Cardiovascular Pharmacology, 1989
Pimobendan (UD-CG 115 BS) is a potent positive inotropic agent with vasodilatory properties. This hemodynamic profile was demonstrated in conscious rabbits chronically instrumented with Doppler flow probes. Pimobendan (10, 30, 100, and 300 micrograms/kg i.v.) increased cardiac output, stroke volume, heart rate, and mesenteric, renal, and hindquarter ...
W. Diederen, J. C. A. Van Meel
  +6 more sources

Studies on cardiotonic agents. VII. Potent cardiotonic agent KF15232 with myofibrillar Ca2+ sensitizing effect.

Chemical and Pharmaceutical Bulletin, 1991
A series of novel 4,5-dihydro-5-methyl-6-(2 or 4-substituted 7-quinazolinyl)-3(2H)-pyridazinones was synthesized and examined for cardiotonic activity in anesthetized dogs. The 4-substituted aminoquinazolines generally showed potent and long-lasting inotropic activity.
Yuji Nomoto, Kazuhiro Kubo, Tetsuji Ohno, Haruki Takai   +3 more
openaire   +5 more sources

Mechanisms of Action of Novel Cardiotonic Agents

Journal of Cardiovascular Pharmacology, 2002
Regulation of myocardial contractility by cardiotonic agents is achieved by an increase in intracellular Ca2+ mobilization (upstream mechanism), an increase in Ca2+ binding affinity to troponin C (central mechanism), or facilitation of the process subsequent to Ca2+ binding to troponin C (downstream mechanism).
Masao Endoh
openaire   +4 more sources

Cardiovascular Properties of a New Cardiotonic Agent, MDL 19205

Journal of Cardiovascular Pharmacology, 1984
The cardiovascular properties of a new cardiotonic agent, MDL 19205, were investigated in anesthetized and conscious dogs and in a dog heart-lung preparation. MDL 19205 (0.1-1 mg/kg), administered to anesthetized dogs by intravenous injection, produced a dose-related increase in cardiac contractile force lasting up to 1 h. It also produced a relatively
Chih Peng Hsieh, James K. Woodward, Lawrence E. Roebel, Richard C. Dage   +3 more
openaire   +4 more sources

Pharmacological Actions of APP 201-533, a Novel Cardiotonic Agent

Journal of Cardiovascular Pharmacology, 1985
APP 201-533 [3-amino-6-methyl-5-phenyl-2(1H)-pyridinone] was investigated in vivo in anesthetized and unanesthetized dogs and pithed open-chest cats and in vitro in guinea pig atria and papillary muscles, skinned muscle fibers from pig hearts, and rat myocardium. Left ventricular dP/dt was increased in anesthetized dogs after intravenous injection of 0.
G Bormann, J. W. Herzig, R. Salzmann, G Scholtysik, R Markstein   +4 more
openaire   +4 more sources

NEWER CARDIOTONIC AGENTS – BENEFICIAL EFFECTS ON NEWBORN MYOCARDIUM [PDF]

Pediatric Research, 1987
Previous data has suggested a deleterious action of Amrinone (Am) on newborn (NB) myocardium. An investigation of the relationship between dose, age, and contractility has been undertaken using isolated right ventricular papillary muscles from NB (0-5 days), juvenile (J) (18-29 days), and adult (A) New Zealand white rabbits.
William F. Friedman, Timothy L Degner, Ross R Ravin, Thomas S. Klitzner   +3 more
openaire   +2 more sources

Cardiotonic Agent SCH00013 Prolongs Survival of Cardiomyopathic Hamsters

Journal of Cardiovascular Pharmacology, 2003
The authors examined the effects of long-term treatment with SCH00013, a novel cardiotonic agent with calcium-sensitizing action, on survival of hereditary cardiomyopathic BIO 14.6 hamsters. Sixty-nine male hamsters at 223 days of age were divided into untreated, SCH00013-low (approximately 1 mg/kg/d), and SCH00013-high (approximately 10 mg/kg/d ...
Yuji Koide, Seiichiro Kawashima, Ryogo Yui, Tadahito Narita, Mitsuo Sakato   +4 more
openaire   +3 more sources

Cardiovascular Pharmacology of the Vasodilator-Cardiotonic Agent, 349U85

Journal of Cardiovascular Pharmacology, 1992
349U85 is a chemically novel, nonglycoside, noncatecholamine cardiotonic-vasodilator agent with a unique cardiovascular profile in vitro and in vivo. 349U85 and milrinone, 10(-6) to 3 x 10(-5) M each, produce concentration-dependent increases in tension development of 33-60% and 37-60%, respectively, with corresponding 5-18% and 17-55% increases in ...
William B. Wastila, Robert P. Steffen
openaire   +4 more sources

The Cardiotonic Agent Amrinone Does Not Increase Anatomic Infarct Size

Journal of Cardiovascular Pharmacology, 1987
The effect of the positive inotropic agent amrinone on anatomic infarct size induced by coronary artery occlusion and reperfusion in dogs is unknown, although previous studies have shown that amrinone increases indices of myocardial ischemia during very brief coronary artery occlusions.
Prabodh M. Mehta, Robert A. Kloner, Colin A. Campbell, Joshua Wynne   +3 more
openaire   +4 more sources